NATICK, Mass., Nov. 25, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce that its wholly owned subsidiary Regenocell, Ltd. is in the final stages of negotiations with several potential new distributors. It is anticipated that one or more will be finalized by year end and begin purchasing cell processing services in the near term. This will have a beneficial impact on revenues generated by the cell processing operations of Regenocell Laboratories, Ltd. in Israel.
It is anticipated that one or more of the new potential distributors will increase patient flow to Regenocell, Ltd. substantially increasing the utilization of existing capacity.
Since 2005, the Company's stem cell therapy has successfully treated over 500 patients. The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live. Over 5 years later patents initially treated are leading active and fulfilling lives.
About RegenoCELL Therapeutics, Inc.
RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients. The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments. Through its wholly owned foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in countries where autologous therapy is permitted.
There are therapies to treat congestive heart failure. But there comes a treatment point when the only option may be a heart transplant. Over 25,000 people are on the transplant lists but fewer than 2,500 receive one. The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.
Peripheral Artery Disease
The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.
Since 2005, the company's stem cell therapy has successfully treated over 500 patients. The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live. Less than a half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel. There the patient's stem cells are extracted and grown from tens of thousands into many millions. The stem cells are primed for angiogenesis or blood vessel formation. The patient then travels to a country where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catheterization laboratory in a procedure similar to angioplasty.
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our inability to predict the extent of our future losses or if or when we will become profitable; (viii) our ability to protect our intellectual property rights; and, (ix) intense competition. The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on 'From 10-Q for the quarter ended September 30, 2011.
RegenoCELL Therapeutics, Inc.
James F. Mongiardo, Chief Executive Officer
SOURCE RegenoCELL Therapeutics, Inc.